Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InSite ties up with Quest on glaucoma test:

This article was originally published in Clinica

Executive Summary

Quest Diagnostics and ophthalmic products company InSite Vision have set up a one-year agreement under which Quest will provide lab services in the US for InSite's OcuGene genetic test for the early prognosis and diagnosis of glaucoma. The OcuGene kit, introduced recently in the US by the Alameda, California company, consists of a pair of buccal brushes used to swab the inside of the patient's cheek. Quest will test the samples for gene mutation at its Nichols Institute site in San Juan Capistrano, California.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel